ARYX THERAPEUTICS, INC. Inactive Instrument
ARYx Therapeutics, Inc. Stock Other OTC
Equities
ARYX
US0433871094
Biotechnology & Medical Research
Financials (USD)
| Sales 2008 | 19.72 | Sales 2009 | - | Capitalization | 88.66M |
|---|---|---|---|---|---|
| Net income 2008 | -31M | Net income 2009 | -33M | EV / Sales 2008 | 4,019,605 x |
| Net cash position 2008 | 29.9 | Net Debt 2009 | 2.37 | EV / Sales 2009 | - |
| P/E ratio 2008 |
-1.76
x | P/E ratio 2009 |
-2.66
x | Employees | - |
| Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More press releases
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.74% | 102B | |
| +2.27% | 96.07B | |
| -1.75% | 21.66B | |
| -17.53% | 20.77B | |
| -7.10% | 18.53B | |
| -40.31% | 16.91B | |
| -28.23% | 13.79B | |
| +0.15% | 13.33B | |
| +20.54% | 10.94B |
